A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Ganaplacide (Primary) ; Artemether/lumefantrine; Lumefantrine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 06 Jan 2020 Planned End Date changed from 22 Sep 2020 to 22 Oct 2020.
- 06 Jan 2020 Planned primary completion date changed from 26 Sep 2019 to 5 Oct 2019.
- 05 Jun 2019 Planned End Date changed from 19 Jun 2020 to 22 Sep 2020.